Ownership Submission
|
FORM 3/A
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
O'HEERON PETE
|
|
2. Date of Event Requiring Statement (Month/Day/Year)
2024-01-24
|
3. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [FBLG]
|
|
(Last)
|
(First)
|
(Middle)
|
|
C/O FIBROBIOLOGICS, INC. , 455 E. MEDICAL CENTER BLVD. SUITE 300
|
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
__X__ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
Chief Executive Officer /
|
|
5. If Amendment, Date Original Filed(Month/Day/Year)
2024-02-08
|
(Street)
|
|
HOUSTON
|
TX
|
77598
|
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Beneficially Owned
|
|
|
1.Title of Security
|
2. Amount of Securities Beneficially Owned
|
3. Ownership Form: Direct (D) or Indirect (I)
|
4. Nature of Indirect Beneficial Ownership
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Date Exercisable and Expiration Date
|
3. Title and Amount of Securities Underlying Derivative Security
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
6. Nature of Indirect Beneficial Ownership
|
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
O'HEERON PETE
C/O FIBROBIOLOGICS, INC.
455 E. MEDICAL CENTER BLVD. SUITE 300
HOUSTON, TX77598
|
X
|
|
Chief Executive Officer
|
|
Signatures
|
/s/ Ruben A. Garcia, by Power of Attorney
|
2024-08-12
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
The Series C Preferred Stock is convertible into the issuer's Common Stock on a 1-for-1 basis and has no expiration date. Upon the closing of the issuer's direct listing, the Series C Preferred Stock will convert, without the payment of additional consideration by or to the holder thereof, into the issuer's Common Stock on a 1-for-1 basis upon any transfer of such shares. For as long as they remain outstanding, the Series C Preferred Stock of the issuer held by the Reporting Person are subject to an irrevocable proxy issued by the Reporting Person in favor and for the benefit of the board of directors of the issuer.
|
|
(2)
|
1/4 of the options vested on January 1, 2024, with the remainder vesting monthly over 36 months.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
